MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity ...Middle East

16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., April 10, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic...

Hence then, the article about metavia doses the first patient in higher dose phase 1 study of da 1726 its glp 1 and glucagon dual agonist for the treatment of obesity was published today ( Friday 10/04/2026 - 03:32 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity )

Also on site :

• Nigerian general killed in Islamic State attack
• Finn Wolfhard Told ‘Malcolm in the Middle’ Creator “F*ck Yeah” To Revival Cameo: “He’s Such A Big Fan”
• Best-Selling Author's Novel Consistently Ranks Among Top Reader Favorites on Goodreads